Click on image to view larger version.

Figure 5 Nasal administration of CM reduced the serum levels of myosin-specific IgG1 antibodies. The levels of anti-myosin antibodies of the IgG1 subclass were measured in serum samples collected on both days 10 and 21 from mice that received CM nasally (right bars, n = 9) and from those that received buffer (left bars, n = 14). The antibody levels are presented as the mean of adjusted optical densities (adjusted ODs, see Methods section) of each group ± SEM. The levels of IgG1 anti-myosin antibodies were significantly reduced in mice that received CM intranasally on both day 10 (p = 0.04) and day 21 (p = 0.04), compared to the control mice that received buffer nasally.